B
진양제약
007370KOSDAQ의약품 제조업60.0 / 100
Reference Date: 2026-04-13
Financial Score30.5 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but Operating Profit is on a declining trend. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Jinyang Pharmaceutical primarily engages in the manufacturing and sales of pharmaceutical products, operating in a high-value, R&D-driven industry. However, growth is constrained by government price controls and intensified competition, with new drug development and international market expansion seen as key future growth drivers.
Number of Employees
219people
Average Salary
58.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
2.53Industry Average 14.808.0Point
Half of industry avg (excellent)
PBR
0.41Industry Average 1.047.0Point
Half of industry avg (excellent)
ROE
15.93Industry Average 4.427.0Point
3.6x industry avg (excellent)
Debt Ratio
12.43Industry Average 11.982.0Point
Higher than industry avg (caution)
Trend 2023~20256.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲13.5% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼24.8% (2-year basis)
ROE Trend
4.0 / 4
Avg ROE 19.8% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (10%, downtrend)
Current 4,620Won52-week high 6,74052-week low 4,370
1-month return3.0Point
1m 0.43% (flat)
Volume trend3.0Point
Volume flat
Detailed Disclosure
5 totalPositive 0Neutral 5Negative 0
- Neutral정기주주총회결과2026-03-27
- Neutral[기재정정]의결권대리행사권유참고서류2026-03-19
- Neutral[기재정정]주주총회소집공고2026-03-19
- Neutral사업보고서 (2025.12)2026-03-18
- Neutral감사보고서제출2026-03-18